Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care

To participate in this activity, please:

Log in Sign Up

Course Credit:

2.5 AAPA Category I Hours
2.5 ACPE Contact Hours
2.5 ANCC Contact Hours
1.25 Pharmacology Hours

Dates:

Opens: 2022-06-30
Closes: 2024-07-01

Target Audience:

The activity is designed for advanced practitioners (nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and pharmacists) who treat patients with multiple myeloma and plasma cell disorders.

This certified activity is supported by educational grants from AbbVie, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; Legend Biotech; Oncopeptides, Inc.; Sanofi Genzyme; and Takeda Pharmaceuticals U.S.A., Inc.

Accreditation Information

Accreditation

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #. This program is designated for up to 2.5 hours (0.25) CEUs) of continuing pharmacy education credit.
The Annenberg Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.5 hours AAPA Category 1 CME credits. Approval is valid until July 01, 2024. PAs should only claim credit commensurate with the extent of their participation.
Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 2.5 contact hours, including 1.25 pharmacology hours, may be earned for successful completion of this activity.

Additional Content Planners

Andrea Edwards, PA-C (Peer Reviewer)

Speaker: Pfizer


Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN (Nurse Planner)

Consultant: Bristol Myers Squibb, GSK, Janssen, Karyopharm, Legend, Oncopeptides, Sanofi, and Takeda.


Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

Harborside and Harborside Medical Education staff have nothing to disclose.

International Myeloma Foundation staff have nothing to disclose.

    Presenting Faculty

  • Kevin Brigle, PhD, ANP

    VCU Massey Cancer Center
    Richmond, Virginia

  • Donna D. Catamero, ANP-BC, OCN®, CCRC

    Mount Sinai Health System
    New York, New York

  • Kathleen Colson, RN, BSN, BS

    Dana-Farber Cancer Institute
    Boston Massachusetts

  • Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN

    Cleveland Clinic Taussig Cancer Institute
    Cleveland, Ohio

  • Rebecca Lu, MS, FNP

    The University of Texas MD Anderson Cancer Center
    Houston, Texas

  • Kimberly Noonan, DNP, ANP-BC, AOCN®

    Dana-Farber Cancer Institute
    Boston, Massachusetts

  • Tiffany Richards, PhD, ANP-BC, AOCNP®

    The University of Texas MD Anderson Cancer Center
    Houston, Texas

  • Sandra Rome, RN, MN, AOCN®, CNS

    Cedars-Sinai Medical Center
    Los Angeles, California

  • Mary Steinbach, DNP, APRN

    Huntsman Cancer Institute University of Utah
    Salt Lake City, Utah

  • Daniel Verina, DNP, RN, ACNP-BC

    Mount Sinai Medical Center
    New York, New York

Downloads

This course has no downloads at this time.

Learning Objectives

  • Discuss symptoms and appropriate management associated with multiple myeloma treatment regimens for patients at different stages, from newly diagnosed through heavily pretreated.
  • Develop awareness of health-care disparities and psychosocial impacts faced by patients with multiple myeloma.
  • Employ strategies for improving patient adherence and satisfaction with treatment outcomes via approaches such as setting expectations and shared decision-making.

Faculty Disclosures

Kevin Brigle, PhD, ANP

Speakers Bureau: AstraZeneca, Bristol Myers Squibb, Karyopharm,Oncopeptides, and Sanofi.
 


Donna D. Catamero, ANP-BC, OCN®, CCRC

Speakers Bureau: Oncopeptides and GSK
Advisory Board: Bristol Myers Squibb, GSK, Legend


Kathleen Colson, RN, BSN, BS

Consultant:  Bristol Myers Squibb, Oncopeptides, and Sanofi.


Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN

Consultant: Bristol Myers Squibb, GSK, Janssen, Karyopharm, Legend, Oncopeptides, Sanofi, and Takeda.


Rebecca Lu, MS, FNP

No relationships to disclose.

Kimberly Noonan, DNP, ANP-BC, AOCN®

No relationships to disclose.

Tiffany Richards, PhD, ANP-BC, AOCNP®

Consultant: Bristol Myers Squibb, GSK, Janssen/Legend, Sanofi, and Takeda.


Sandra Rome, RN, MN, AOCN®, CNS

No relationships to disclose.

Mary Steinbach, DNP, APRN

Speakers Bureau: GSK and Karyopharm


Daniel Verina, DNP, RN, ACNP-BC

Speakers Bureau: Bristol Myers Squibb, GSK, Janssen,Karyopharm, Sanofi, and Takeda.